Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers.

about

Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers.

Item

http://www.wikidata.org/entity/Q55511795

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Pharmacokinetics of Tedizolid ...... ination in Healthy Volunteers.

@en

Pharmacokinetics of Tedizolid ...... ination in Healthy Volunteers.

@nl

type

Item

label

Pharmacokinetics of Tedizolid ...... ination in Healthy Volunteers.

@en

Pharmacokinetics of Tedizolid ...... ination in Healthy Volunteers.

@nl

prefLabel

Pharmacokinetics of Tedizolid ...... ination in Healthy Volunteers.

@en

Pharmacokinetics of Tedizolid ...... ination in Healthy Volunteers.

@nl

P1476

Pharmacokinetics of Tedizolid ...... ination in Healthy Volunteers.

@en

P2093

Philippe Prokocimer

http://www.w3.org/2001/XMLSchema#string

Shawn Flanagan

http://www.w3.org/2001/XMLSchema#string

Sonia L Minassian

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of oral pseudoephedrine on blood pressure and heart rate: a meta-analysis.

Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.

In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.

In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.

Linezolid: a review of safety and tolerability.

The oxazolidinones: past, present, and future.

Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.

Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.

Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr.

P31

scholarly article

P356

10.3390/JCM7060150

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29899212

http://www.w3.org/2001/XMLSchema#string

P932

6025247

http://www.w3.org/2001/XMLSchema#string